BioCentury | Dec 31, 2020
Distillery Therapeutics

Protease inhibitor SERPINB9 as a melanoma, breast cancer target

DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer Inhibiting SERPINB9, a serine protease inhibitor, could treat melanoma and breast cancer. In a melanoma mouse model, tumor-specific SERPINB9 knockout reduced tumor size and the number of melanoma...
BioCentury | Oct 3, 2019

SERPINB1 and CXCR6 inhibition for multiple sclerosis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Blocking the leukocyte esterase inhibitor SERPINB1 or the chemokine receptor CXCR6 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, systemic knockout...
BioCentury | Aug 3, 2019
Emerging Company Profile

Bringing CAR T to India

A company formed this year in Bangalore by Kiran Mazumdar-Shaw, Kush Parmar and Siddhartha Mukherjee plans to bring a CAR T therapy to cancer patients in India for about $50,000 per treatment. That cost, which...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Aug 21, 2018
Preclinical News

Two algorithms could better predict response to checkpoint inhibitors

While checkpoint inhibitors have revolutionized immunotherapy, many patients don't respond to the inhibitors, and there are currently no accurate diagnostics to predict who will respond. Two papers in Nature Medicine put forth algorithms that use...
BioCentury | Aug 9, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Oct 31, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs A panel of five genomic loci could help predict the risk of food allergy. Genome-wide association studies in 1,547 children with food allergies and 4,897 healthy volunteers identified associations between the disease and...
BioCentury | Oct 24, 2017
Preclinical News

GWAS identify new risk loci in allergies and breast cancer

Three genome-wide association studies (GWAS) have identified new genetic markers associated with an increased risk of food allergies and breast cancer. In a paper published in Nature Communications , researchers at the Max Delbrueck Center for...
BioCentury | Oct 11, 2017
Preclinical News

Researchers optimize gene editing for SCID

Researchers from Ospedale San Raffaele and elsewhere used zinc finger nuclease and CRISPR- Cas9 (CRISPR-associated protein 9)-based gene editing to correct hematopoietic stem/progenitor cells in animal models of SCID-X1, demonstrating improved gene editing protocols that...
Items per page:
1 - 10 of 74